Form 4 for ALLO Allogene Therapeutics, Inc.
Accepted 2022-04-04 00:00:00 ET · period of report 2022-03-31 · accession 0001883111-22-000001 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-04-04 | 2022-03-31 | ALLO | PF Equity Holdings 2 B.V. | 10% | J - Other | $0.00 | -22.03M | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-31 | J | D | 22,032,040 | $0.00 | 0 | D | — | — | (F1) Shares transferred to its parent entity, Pfizer Inc., for no cash consideration. |